BOHEMIA, NY, January 3, 2023 /PRNewswire/ — Sartorius, a leading international partner in life science research and the biopharmaceutical industry, announces Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after almost 35 years. Sartorius North Americaheadquarters i Bohemia, New Yorkcurrently employs more than 3,000 employees across 17 locations i the United States and Canada.
Mr. Phelan has many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Prior to that, he was Head of Operations at the Sartorius site i Marlborough, Massachusetts. Prior to that, he held leadership roles at GE Healthcare and Merck Millipore. Mr Phelan has degrees in chemistry and experimental physics from the University of Ireland.
“There are many innovations in the biopharmaceutical industry North America, which is also home to many of our customers. Therefore, the region is and will be Sartorius’ most important markets. With his broad experience in the industry, Maurice will help us further expand the activities of our laboratory and bioprocessing division, facilitating cross-functional divisional alignment and business development in the region,” said René Fáber, member of the Sartorius Executive Board.
In the context of fundamentally strong market dynamics, Sartorius is investing heavily in building new resources i North America. In Yauco, Puerto Ricothe company has expanded its cleanroom capacity for manufacturing products such as filters and disposable bags, with construction underway in Ann Arbor, Michiganfor a state-of-the-art 130,000 square foot plant to open by the end of 2023, creating a Center of Excellence for Bioanalysis in North America. In 2021, Sartorius opened a 40,000 square foot Customer Interaction Center in Marlborough, Massachusettsto optimize factory acceptance testing and commission new bioprocess equipment.
Profile of Sartorius
The Sartorius Group is a leading international partner in life science research and the biopharmaceutical industry. With innovative instruments and consumables, the Group’s Laboratory Products & Services Division focuses on serving the needs of research and quality control laboratories at pharmaceutical and biopharmaceutical companies and academic research institutions. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotechnological medicines and vaccines safely and efficiently. The Group is growing by double digits on average every year and its portfolio is regularly expanding through acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of 3.45 billion euros. At the end of 2021, almost 14,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Senior Vice President, Benchmark Strategies